Form 4: Entrada Therapeutics Director Sells Shares Under Pre-Arranged Trading Plan

Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc., sold 27,000 shares of common stock for $7.502 per share through pre-arranged trading plans.

Summary

• Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc. (TRDA), reported the sale of common stock.
• A total of 27,000 shares were sold on July 9, 2025, at a price of $7.502 per share.
• The sales were executed through two entities: 20,065 shares by 5AM Ventures V, L.P., and 6,935 shares by 5AM Opportunities I, L.P.
• Following these transactions, 5AM Ventures V, L.P. beneficially owns 3,163,066 shares, and 5AM Opportunities I, L.P. beneficially owns 1,093,313 shares.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale of shares by a director and 10% owner is generally a negative signal, but the fact that it was conducted under a Rule 10b5-1 plan mitigates the negative sentiment significantly, as it implies a pre-scheduled transaction rather than a reaction to new, adverse information. The score is slightly negative due to the reduction in insider ownership.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating it was pre-scheduled and not based on new, non-public information, which can mitigate negative interpretations of insider selling.

Negatives

• A Director and 10% owner selling shares, even under a 10b5-1 plan, can be perceived negatively by the market as it reduces insider ownership and may signal a lack of confidence or a need for liquidity.
• The sale price of $7.502 per share is the price at which the shares were sold, which could be below previous highs or market expectations.

Risks

• Increased market speculation regarding insider sentiment due to the sale of shares by a director and significant shareholder.
• Potential negative impact on investor confidence if the market misinterprets the sale as a lack of belief in the company's future, despite the 10b5-1 plan.

Industry Context

Insider transactions, particularly sales by directors and significant shareholders, are closely watched in the biotechnology and pharmaceutical sectors as they can sometimes signal management's view on future prospects or liquidity needs. However, sales under Rule 10b5-1 plans are common and generally viewed as less indicative of negative sentiment compared to unscheduled sales.

Related Party Transactions

• Kush Parmar, a Director and 10% owner, is a managing member of the general partners for 5AM Ventures V, L.P. and 5AM Opportunities I, L.P., which are the entities that executed the share sales. This represents an indirect transaction by a related party.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to short-term price volatility, although the 10b5-1 plan mitigates this.

Key Dates

Recommendation

Keywords

Entrada Therapeutics, TRDA, SEC Form 4, Insider Trading, Stock Sale, Kush Parmar, 5AM Ventures, 10b5-1 Plan, Director Sale, 10% Owner